Flatiron Health’s Post

Join Citeline's expert analysts June 12 as they dissect the major announcements, clinical trial results, and emerging therapies revealed at this year’s ASCO Annual Meeting. Each year, the must-attend event provides invaluable insights, essential for shaping investment decisions, informing pipeline strategies, and discovering potential licensing opportunities — all critical to maintain a competitive edge in the oncology space. Register for the webinar today to tap into the key insights: https://ow.ly/8fqn50RUkgc. #ASCOAnnualMeeting #ClinicalTrials #ExpertAnalysts #CompetitiveEdge #EmergingTherapies

Join Citeline's expert analysts June 12 as they dissect the major announcements, clinical trial results, and emerging therapies revealed at this year’s ASCO Annual Meeting. Each year, the must-attend event provides invaluable insights, essential for shaping investment decisions, informing pipeline strategies, and discovering potential licensing opportunities — all critical to maintain a competitive edge in the oncology space. Register for the webinar today to tap into the key insights: https://ow.ly/yZAp50S0rBy. #ASCOAnnualMeeting #ClinicalTrials #ExpertAnalysts #CompetitiveEdge #EmergingTherapies

In 2023, Friends of Cancer Research played a key role in shaping and informing the landscape of oncology drug development and regulatory policy to bring advancements in treatment to patients through collaborative and innovative initiatives. Read our full 2023 Scientific Report here: https://lnkd.in/eHKxigfT #FriendsSR23

Join Citeline's expert analysts June 12 as they dissect the major announcements, clinical trial results, and emerging therapies revealed at this year’s ASCO Annual Meeting. Each year, the must-attend event provides invaluable insights, essential for shaping investment decisions, informing pipeline strategies, and discovering potential licensing opportunities — all critical to maintain a competitive edge in the oncology space. Register for the webinar today to tap into the key insights: https://ow.ly/ehL950S0rvr. #ASCOAnnualMeeting #ClinicalTrials #ExpertAnalysts #CompetitiveEdge #EmergingTherapies

Getting ready for another exciting (hybrid) The Cancer Drug Development Forum (CDDF) Annual Conference in couple weeks! This year's theme is: "Changing paradigms to accelerate oncology drug development" that will bring together regulators, payers, patient groups, healthcare providers and industry for an open discussion on effective #stakeholderengagement to shift existing paradigms to meet future of cancer drug development. Personally, I'm honored to team up with Axel Glasmacher again this year for a timely session on upcoming regulatory changes in Europe and continuing our conversations on #diversity in #clinicaltrials in Europe. We had a robust discussion with our panelists last night and some of the areas I'm looking forward to touch during the discussions are: ⭐ Diversity from European lens ⭐ What success looks like and how to achieve diversity goals ⭐ Role of regulations (do they help or hinder?) ⭐ Data requirements and utilization of such data Don't miss out on the exciting discussions and sign up today! 👉 https://lnkd.in/e4mEWDsV

Each year the ASCO Annual Meeting reveals cutting-edge clinical trial results, new drug approvals, innovative treatments, and emerging trends in oncology. The insights shared are essential for anyone seeking market intelligence to shape strategic decisions and investments. Join us for a live webinar June 12, where Citeline's team of expert analysts will dissect major announcements from the event and explore their implications for you and your business. Don’t miss out. Register for the webinar today: https://ow.ly/uAT050S8A6q. #ASCOAnnualMeeting #MarketIntelligence #ClinicalTrials #OncologyTrends #WebinarAlert #OncologyInsights

Each year the ASCO Annual Meeting reveals cutting-edge clinical trial results, new drug approvals, innovative treatments, and emerging trends in oncology. The insights shared are essential for anyone seeking market intelligence to shape strategic decisions and investments. Join us for a live webinar June 12, where Citeline's team of expert analysts will dissect major announcements from the event and explore their implications for you and your business. Don’t miss out. Register for the webinar today: https://ow.ly/pA1A50S0BIg. #ASCOAnnualMeeting #MarketIntelligence #ClinicalTrials #OncologyTrends #WebinarAlert #OncologyInsights

Alternative Designs for Dose-Finding Trials: AACR President-elect Patricia M. LoRusso and M.D. Anderson statistician Ying Yuan addressed this topic in a session at the FDA-AACR Workshop on Optimizing Dosages for Oncology Drug Products. The session shared the latest innovations in designing early phase trials to enhance understanding of therapeutic range for novel therapies and speed up development. #AACRSciencePolicy

Another good workshop, this one specific to those working in oncology; there is a three-fold focus for the workshop: [1] to discuss best practices and methods for evaluating the totality of nonclinical and clinical data, and incorporating modeling and simulation to identify optimized dosages; [2] to consider innovative clinical trial designs; and [3] to highlight ongoing efforts in various forums that include academia, industry, and regulatory agencies in the current knowledge and thinking for dose selection https://lnkd.in/g8zzZ92h

We released our Friends of Cancer Research 2023 Scientific Report today: bit.ly/3SE0bml. The report contains all of our white papers and publications to serve as a resource for those in the drug development and regulatory space. Over the course of 2023 our work touched on several key themes: 1. Patient-Focused Drug Development: Advancing Patient-Centered Technologies and Trial Designs 2. Real-World Evidence: Leveraging RWD for Insights on Real-World Response 3. Innovative Drug Development: Insights for Advancing Oncology Trials and Therapies 4. Complex Biomarkers: Aligning Best Practices to Support Future Utilization Through our collaborations and expertise from our partners, we are able to develop proposals and solutions that help shape and inform the landscape of oncology drug development and regulatory policy to bring advancements in treatment to patients. Read the full report here: bit.ly/3SE0bml #FriendsSR23 #cancerresearch #regulatoryscience #breakthroughs